Skip to content

NS PHARMA

Active Private limited companyfounded 2010active for 16 yearsRue d'Auvelais 43, 5060 SambrevilleKBO/BCE: BE 0822.653.238

Lifetime

15 annual accounts with figures on one time axis
peak of €258,473 in 2020
€215,691▼ 6.2%
lowest -€40,281 in 2011
€35,970▼ 14.9%
peak of €269,360 in 2025
€269,360▲ 10.2%
€422,295▼ 1.9%
peak of 1.2 FTE in 2020
-not published
Board1 name since 2022
1 director
Documentsfilings and deeds
02-02-20262 days late
2025micro format
Cash from €25,718 to €12,799

Key points

from the 2025 annual accounts

Equity

€269,360 ▲ 10.2%

NS PHARMA has made a profit without a break since 2014.

Filings

15 annual accounts since 2011
deadline201520202025

Ten of the last ten came late. The 2019 accounts came in latest, 35 days after the end of the period.

Position in the sector

€269,360

More equity than 89% of companies in retail trade. The sector median is €40,794, over 25,465 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 34,728 companies had the same profile as NS PHARMA has now. Each dot stands for 87 companies, two years later.

95.2%
were still trading
4.0%
stopped another way
0.7%
went bankrupt
  • Micro
  • 10 to 20 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,994 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 34,728 companies, not a prediction for NS PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
  • 100 sharesdeed of 08-02-2010
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0822653238
changes role from manager to director Legal-form conversion: from private limited company (pre-2019) to private limited company · Discharge granted to · General meeting of 27-11-2023 · Gazette deed
is in office as manager Gazette deed
First establishment Rue d'Auvelais 43, Sambreville
All 26 events

Comparable companies

same main activity, similar in size and age
Company
NS PHARMA Sambreville €691,656 €215,691 38.9% -
PROXYPHARMA LLB La Bruyère €707,554 €216,577 75.3% 2.1
PHARMACIE FRANQUIN VERONIQUE Florennes €675,555 €225,401 30.2% 2.2
APOTHEEK DE ZUIDFLANK Assenede €722,912 €209,164 58.4% 1.9
Merelbeke Farma Merelbeke-Melle €670,499 €212,551 24.0% 2.2
APOTHEEK VIRO Wervik €649,766 €211,002 69.2% 1.2
Apotheek Snykers-Lahaut Beveren-Kruibeke-Zwijndrecht €644,410 €221,407 83.9% 1.2

These companies have the same main activity as NS PHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €644,000 and €723,000, founded between 2008 and 2011.

Official details

Source: KBO
Status
Active since 27-01-2010Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730
Establishment unit
2.185.770.4825060 Sambreville, since 15-03-2010
Financial year end
30 June
Peppol
Reachable since 18-12-2025
Company details

Annual accounts to 30-06-2025

≈ €760,000estimated
€691,656▲ 2.5%
Employeeson 30-06-2025
2=
Filing
Filed on 02-02-2026
Financials

Insights on NS PHARMA

NS PHARMA files the micro format. That format states no turnover. The gross margin rose from €173,850 in 2011 to €215,691 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about NS PHARMA

What is the company number of NS PHARMA?
The company number of NS PHARMA is 0822.653.238. The VAT number is the same number with BE in front: BE 0822.653.238.
Where is NS PHARMA based?
The registered office is at Rue d'Auvelais 43, 5060 Sambreville.Company details
What does NS PHARMA do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of NS PHARMA?
NS PHARMA is a private limited company (BV).
When was NS PHARMA founded?
NS PHARMA was founded on 27-01-2010.
Is NS PHARMA still active?
Yes, NS PHARMA is an active enterprise in the KBO register.
How many employees does NS PHARMA have?
NS PHARMA had an average of 1.2 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of NS PHARMA?
The turnover in financial year 2025 is about €760,000. This figure is estimated from the gross margin of €215,691 and 37 comparable companies (NACE 477). It probably lies between €570,000 and €1.3m.
Is NS PHARMA profitable?
In financial year 2025, NS PHARMA made a profit of €35,970.
Where can I find the annual accounts of NS PHARMA?
NS PHARMA filed 15 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of NS PHARMA due?
NS PHARMA must file the annual accounts for financial year 2026 by 31-01-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.